Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00437151 · ClinicalTrials.gov registry record · Phase 4

Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%

A Phase 4 study of Acne, sponsored by Galderma R&D.

Completed
Registry status
Phase 4
Development phase
61
Enrollment target
1
Study location

NCT00437151 is a Phase 4 study of Acne that has completed, run by Galderma R&D. The registered enrollment target is 61 participants, below the 140-participant average among 26 other Acne trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00437151, a Phase 4 study of Acne, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 4
Development phase
61 participants
Enrollment target
1
Study location

Study Summary

The primary objective of this study is to investigate potential differences in treatment adherence by teenagers among four interventions during treatment for acne.

Conditions Studied

Interventions

  • OTHER More frequent than normal office visits
  • OTHER Electronic reminders (voice, e-mail, text messages)
  • OTHER Parenteral involvement / intervention reminders
  • OTHER No intervention or reminders

Study Locations (1)

North Carolina

  • Wake Forest School of Medicine - Winston-Salem

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2006-06
Est. Completion 2007-06
Phase Phase 4

Sponsor

Galderma R&D

158 total trials

What the Registry Record Tells You About NCT00437151

The ClinicalTrials.gov registry entry for NCT00437151 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 140-participant average among 26 other Acne trials with a reported enrollment target (56% lower). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne appearing as the primary indexed condition, and to 4 interventions - of which More frequent than normal office visits is the first listed.

NCT00437151 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00437151 about?

NCT00437151 is a clinical study titled "Analysis of Adherence & Associated Factors in Teenagers Undergoing Treatment of Acne Vulgaris With Differin® Gel 0.1%". The primary objective of this study is to investigate potential differences in treatment adherence by teenagers among four interventions during treatment for acne.

What is the current status of trial NCT00437151?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2006-06. Estimated completion is 2007-06.

What conditions does trial NCT00437151 study?

This clinical trial studies the following conditions: Acne.

What interventions are being tested in trial NCT00437151?

The interventions under investigation include: More frequent than normal office visits (OTHER), Electronic reminders (voice, e-mail, text messages) (OTHER), Parenteral involvement / intervention reminders (OTHER), No intervention or reminders (OTHER).

Who is sponsoring clinical trial NCT00437151?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00437151 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Acne

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.